Cargando…
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and...
Autores principales: | Di Lernia, V, Bardazzi, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743637/ https://www.ncbi.nlm.nih.gov/pubmed/26889081 http://dx.doi.org/10.2147/DDDT.S82599 |
Ejemplares similares
-
Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018) -
Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis
por: Vesely, Matthew D., et al.
Publicado: (2016) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016) -
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013) -
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial
por: Abe, Masatoshi, et al.
Publicado: (2017)